Related Experiment Video
Updated: Jun 22, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products
Swarnali Acharyya1, Katherine J Ladner, Lori L Nelsen
1Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus 43210, USA.
Abstract:
Cachexia is a syndrome characterized by wasting of skeletal muscle and contributes to nearly one-third of all cancer deaths. Cytokines and tumor factors mediate wasting by suppressing muscle gene products, but exactly which products are targeted by these cachectic factors is not well understood. Because of their functional relevance to muscle architecture, such targets are presumed to represent myofibrillar proteins, but whether these proteins are regulated in a general or a selective manner is also unclear. Here we demonstrate, using in vitro and in vivo models of muscle wasting, that cachectic factors are remarkably selective in targeting myosin heavy chain. In myotubes and mouse muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA-dependent mechanism. Likewise, colon-26 tumors in mice caused the selective reduction of this myofibrillar protein, and this reduction correlated with wasting. Under these conditions, however, loss of myosin was associated with the ubiquitin-dependent proteasome pathway, which suggests that mechanisms used to regulate the expression of muscle proteins may be cachectic factor specific. These results shed new light on cancer cachexia by revealing that wasting does not result from a general downregulation of muscle proteins but rather is highly selective as to which proteins are targeted during the wasting state.
Insights
Cancer cachexia selectively targets myosin heavy chain, a key myofibrillar protein, through RNA-dependent mechanisms and the ubiquitin-proteasome pathway, not general muscle protein downregulation.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cachexia, a cancer-associated wasting syndrome, causes significant mortality.
- The specific muscle gene products targeted by cachectic factors remain poorly understood.
- It is unclear if muscle protein regulation during cachexia is general or selective.
Purpose of the Study:
- To investigate the selectivity of cachectic factors in targeting muscle proteins.
- To elucidate the mechanisms underlying myosin heavy chain reduction in muscle wasting.
Main Methods:
- In vitro studies using myotubes.
- In vivo studies using mouse models with colon-26 tumors.
- Analysis of gene expression and protein degradation pathways.
Main Results:
- Cachectic factors selectively reduced myosin heavy chain expression.
- Tumor necrosis factor-alpha (TNF-alpha) plus interferon-gamma (IFN-gamma) reduced myosin via an RNA-dependent mechanism.
- Myosin loss in tumor-bearing mice involved the ubiquitin-dependent proteasome pathway.
Conclusions:
- Cancer cachexia involves selective targeting of specific myofibrillar proteins like myosin heavy chain.
- Muscle wasting is not a generalized suppression of muscle gene products.
- The mechanisms regulating protein expression during cachexia can be factor-specific.
More Related Videos
12:19Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin (sh)RNA
Published on: February 12, 2020
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...